Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Vanta Bioscience Ltd Performance

Today's Low
71.66
arrowIcon
Today's High
75.24
52 Wk Low
37.00
arrowIcon
52 Wk High
101.64


Open

71.66

Traded Value (Cr)

4.51 L

Prev. Close

71.66

VWAP

74.69

Volume

6,000

Face Value

10

Vanta Bioscience Ltd Fundamentals

Market Cap
₹ 47 Cr
P/E Ratio (TTM)
0.00
P/B Ratio
2.71
Debt to Equity
3.36
ROE
-26.25 %
EPS (TTM)
0.00
Dividend Yield
0.00%
Book Value
27.75

Click here to know more about Fundamentals

Vanta Bioscience Ltd Financials

Vanta Bioscience Ltd Financials

Vanta Bioscience Ltd Shareholding Pattern

Held By Mar 2024 Sep 2023 Mar 2023 Sep 2022
Promoters 69.36 % 69.36 % 69.36 % 69.36 %
Retail 25.97 % 26.77 % 26.77 % 26.56 %
Others 4.67 % 3.87 % 3.87 % 4.08 %
FII 0.00 % 0.00 % 0.00 % 0.00 %
Mutual Funds 0.00 % 0.00 % 0.00 % 0.00 %

Promoters

69.36%

Retail

25.97%

Others

4.67%

FII

0.00%

Mutual Funds

0.00%

Promoters

69.36%

Retail

26.77%

Others

3.87%

FII

0.00%

Mutual Funds

0.00%

Promoters

69.36%

Retail

26.77%

Others

3.87%

FII

0.00%

Mutual Funds

0.00%

Promoters

69.36%

Retail

26.56%

Others

4.08%

FII

0.00%

Mutual Funds

0.00%

Resistance and Support

₹0.00

PIVOT

resistance-arrow
Resistance
First Resistance₹0.000
Second Resistance₹0.000
Third Resistance₹0.000
support-arrow
Support
First Resistance₹0.000
Second Resistance₹0.000
Third Resistance₹0.000

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day4,500
Week6,0006,000100.00
1 Month5,1255,45599.09
6 Months000.00

About Vanta Bioscience Ltd

Vanta Bioscience Limited was originally incorporated as a private limited company on 29th April 2016 with the name 'Vanta Bioscience Private Limited'. The Company was converted into a public limited company and consequently, the name of the Company was changed to 'Vanta Bioscience Limited' on 17th March 2017. The Promoters of the Company are Mohan Krishna Mulakala, Dopesh Raja Mulakala, Dr. Vyasmurti Madhavrao Shingatgeri, Dr. Soumya Simhadri, Shravan Chintapatla, Karishma Mulakala, Sajan Kiran Mulakala, Pradeep Chowdary and Dr. Chandrasekhar Rao Simhadri. Vanta Bioscience(VBS) is a preclinical contract research organization, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition, it also provides risk assessment services for evaluatingthe safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. VBS also provides expert services for determination of health based exposure limits (e.g. permitted daily exposure (PDE) or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers. VBS entered into an asset transfer agreement dated February 18, 2016 with Kemin Industries South Asia Private Limited, Chennai for the purchase of fully operational toxicology facility Vanta Bioscience' situated at Plot K2B, SIPCOT Industrial Estate, Gummidipundi, Chennai. The Company has taken possession of the said preclinical CRO facility at Gummidipundi, Chennai and has commenced commercial operations thereat from April 1, 2017. Currently the company is mainly doing previous pending research work and are also getting new work from existing clients of Vanta Bioscience' erstwhile division of Kemin Industries South Asia Private Limited. One of the major services of VBS is conducting variety of in vitro (cell, tissue and organisms) and in vivo (animal) toxicology studies for its diverse clients as per various regulatory requirements from across the world. Toxicology is a branch of biology, chemistry, and pharmacology concerned with the study of the adverse effects of chemicals on living organisms. It also studies the harmful effects of chemical, biological and physical agents in biological systems that establish the extent of damage in living organisms. VBS has state of the art facilities and infrastructure necessary for conduct of all kind of toxicology studies for Chemicals, Pharmaceuticals, Cosmetics, Agrochemicals like Pesticides, Insecticides, Excipients, Novel Feed Additives. The data generated from these studies are submitted to regulatory agencies worldwide before they are put in use for the consumption of domestic animals and human being. In addition, VBS also conducts preclinical proof-of-concept (PoC) studies for novel pharmaceuticals and products intended for new indications in variety of animal models of human diseases through a robust process of validation.

Managing Director

Dopesh Raja Mulakala

Founded

2016

NSE Symbol

Vanta Bioscience Ltd Management

NameDesignation
Mohan Krishna MulakalaChairman
Dopesh Raja MulakalaManaging Director
Vyasmurti Madhavrao ShingatgeriWhole-time Director
Padmanabhuni Venkata AppajiIndependent Director
Zoheb SayaniCompany Secretary
Sadhanala Venkata RaoWhole Time Director & CEO
Yogeswara Rao DandaAddtnl Independent Director

Vanta Bioscience Ltd News

Vanta Bioscience wins order of Rs 1.2 cr
Vanta Bioscience wins order of Rs 57 lakh
Vanta Bioscience to conduct board meeting
On 14 November 2023
Vanta Bioscience to convene AGM
On 30 September 2023
Vanta Bioscience to conduct board meeting
On 10 August 2023
Vanta Bioscience to conduct AGM
On 31 December 2022
Vanta Bioscience schedules board meeting
On 14 November 2022
Vanta Bioscience to hold board meeting
On 30 May 2022
Vanta Bioscience schedules AGM
On 31 December 2021
Vanta Bioscience to announce Quarterly Result
On 11 November 2021

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
GODREJAGRO₹ 10,665 Cr
₹ 554.90
(-5.31 %)
29.87
RTNINDIA₹ 9,684 Cr
₹ 70.06
(-3.03 %)
20.25
THOMASCOOK₹ 9,360 Cr
₹ 198.90
(-4.74 %)
115.64
CMSINFO₹ 6,501 Cr
₹ 399.45
(-1.33 %)
20.31
SIS₹ 6,036 Cr
₹ 418.90
(-0.08 %)
32.27

Vanta Bioscience Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Vanta Bioscience Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Vanta Bioscience Ltd's share price is ₹75.20 as of May 3, 2024

Vanta Bioscience Ltd's P/E ratio is 0.00 times as of May 3, 2024.

Vanta Bioscience Ltd's most recent financial reports indicate a price-to-book ratio of 2.71, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Vanta Bioscience Ltd's market is 47 Cr as on May 3, 2024.

The current financial records of Vanta Bioscience Ltd show a -26.25% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Vanta Bioscience Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Vanta Bioscience Ltd's 52-week high and low as of May 3, 2024 are ₹75.24 and ₹71.66 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Vanta Bioscience Ltd stands at 69.36%. During the same period, Institutional Investors have shown a slight values are equal in their holdings, values are equal from 0.00% to 0.00%.